Covidien adds $100m CNS outfit to 'for sale' pharma arm
This article was originally published in Scrip
Executive Summary
Mallinckrodt, the pharmaceuticals business unit of Covidien has agreed to acquire CNS Therapeutics for around $100 million. The privately held specialty pharmaceutical company is focused on developing and commercialising products for site-specific administration to the central nervous system to treat neurological disorders and intractable chronic pain.